An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes

@inproceedings{Zhang2012AnAA,
  title={An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes},
  author={Liwen Zhang and Timothy McCabe and Jon Condra and Yan G. Ni and Laurence B. Peterson and Weirong Wang and Alison M. Strack and Fubao Wang and Shilpa Pandit and Holly A. Hammond and Dana D Wood and Dale W. Lewis and Ray da Silva Rosa and Vivienne Halili Mendoza and Anne Marie Cumiskey and Douglas G. Johns and B. C. Hansen and Xun Shen and Neil S.M. Geoghagen and Kristian K. Jensen and Lei Zhu and Karol Wietecha and Douglas Wisniewski and Lingyi Huang and Jing Zhang Zhao and Robin E. Ernst and Richard Owen Hampton and Peter Haytko and Frances Ansbro and Shannon D Chilewski and Jayne Chin and Lyndon J. Mitnaul and Andrea Pellacani and Carl P. Sparrow and Zhiqiang An and William R. Strohl and Brian K. Hubbard and Andrew S. Plump and Daniel Blom and Ayesha Sitlani},
  booktitle={International journal of biological sciences},
  year={2012}
}
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising therapeutic target for treating coronary heart disease. We report a novel antibody 1B20 that binds to PCSK9 with sub-nanomolar affinity and antagonizes PCSK9 function in-vitro. In CETP/LDLR-hemi mice two successive doses of 1B20, administered 14 days apart at 3 or 10 mpk, induced dose dependent reductions in LDL-cholesterol (≥ 25% for 7-14 days) that correlated well with the extent of PCSK9 occupancy by the antibody. In… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 38 CITATIONS, ESTIMATED 51% COVERAGE

76 Citations

01020'13'15'17'19
Citations per Year
Semantic Scholar estimates that this publication has 76 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 47 REFERENCES

A proprotein convertase subtilisin-like/kexin type 9 (PCSK9)-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces free circulating PCSK9 and LDL-cholesterol

  • Ni Y.G, S DiMarco, +7 authors Cummings R.T
  • J Lipid Res
  • 2011
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…